TGFB1 and neoplasm: By analyzing molecular features of responder patients compared to non-responder ones in the population enrolled in the IMvigor210 trial, Mariathasan and collegues found that TGF-β gene expression was significantly associated with the resistance to immunotherapy and with a shorter overall survival, especially in the presence of the “excluded tumor-immune phenotype” (80).